Form 8-K · Current Report · Filed 2024-02-02
Regeneron Pharmaceuticals Reports Q4 2023 Financial Results
Regeneron Pharmaceuticals, Inc. reported its financial results for the fourth quarter and full year of 2023, showing an 8% increase in full-year revenues to $13.12 billion and a 31% increase in Dupixent global net sales to $11.59 billion. The company's total net product sales grew by 1% to $3.43 billion in Q4 2023, and net income decreased by 3% to $1.16 billion. Regeneron also provided financial guidance for 2024, projecting GAAP R&D expenses between $4.820 billion and $5.070 billion and GAAP SG&A expenses between $2.890 billion and $3.090 billion.
- Filer
- Regeneron Pharmaceuticals, Inc. REGN · NASDAQ
- Filed
- Accession
- 0001804220-24-000006
- CIK
- 0000872589
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$957.78
Next session
-2.2%
Since filing
-20.4%
Latest close
$762.63
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from REGN reporting the same item, with the next session's move:
Exhibits (1)
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Never miss another REGN filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.